BW-40202

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameBW-40202
Drug Alias NameBW-40202BW40202
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement factor B inhibitors
TargetsComplement factor B
Therapy Area/IndicationsComplement-Mediated DiseasesHemoglobinuria, ParoxysmalNephrosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Argo Biopharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Argo Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsComplement-Mediated DiseasesHemoglobinuria, ParoxysmalNephrosis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A